The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5-Reference-Cited by-同舟云学术

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

Published:2017-01-03 Issue:1 Volume:5 Page:31-40
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Schey Steve,Montero Luis Felipe Casado,Stengel-Tosetti Chloe,Gibson Craig J.,Dhanasiri Sujith

Funder

Celgene

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s40487-016-0037-8.pdf

Reference19 articles.

1. Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi133–7.

2. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36(Suppl 1):S3–12.

3. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076–84.

4. European Medicines Association (EMA). Summary of opinion (post authorization): Revlimid (lenalidomide). 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000717/WC500179310.pdf . Accessed 06 March 2016.

5. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–17.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients;Journal of Medical Economics;2020-07-27

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide

;Clinical Interventions in Aging;2020-05

3. Balancing patient value and payer cost in hematologic malignancies: can it be done?;Expert Review of Pharmacoeconomics & Outcomes Research;2018-03-04